European Companies Search Engine
UK funding (£457,026): Novel mechanisms of necroptosis subversion by human cytomegalovirus Ukri1 Apr 2023 UK Research and Innovation, United Kingdom
Overview
Text
Novel mechanisms of necroptosis subversion by human cytomegalovirus
| Abstract | Human cytomegalovirus (HCMV) infects most people worldwide, and establishes a persistent, lifelong infection. Although infected individuals are not usually ill, in immunocompromised patients such as transplant recipients the disease can be devastating, suffering organ rejection, multi-organ failure and even death. Furthermore, unborn babies are at particular risk from HCMV, both in mothers infected during pregnancy and mothers who already have the virus. Overall ~1/100 pregnancies are affected, and HCMV is the leading infectious cause of deafness and intellectual disability in children, and one of the most significant viral causes of birth defects. One of the first lines of defence against HCMV and other viruses are 'cell death pathways', by which infected cells die to prevent viral spread. To counteract this defence, and promote their successful replication, some viruses including HCMV inhibit these cellular pathways. We aim to understand how HCMV prevents cell death. We have made the crucial discovery that a viral protein called UL36 inhibits a key cell death pathway called necroptosis. Furthermore, our initial data suggests the existence of other, as yet undiscovered HCMV inhibitors of cell death. Critically, a detailed understanding of how UL36 and other HCMV necroptosis inhibitors function will enable us to develop new antiviral treatments that restore necroptosis as a vital defence against infection. We will (1) identify and characterise new ways HCMV inhibits necroptosis (2) determine how HCMV targets necroptosis pathway components for destruction; (3) gain a structural understanding of how each viral necroptosis inhibitor interacts with its cellular protein target. To achieve these aims, we will study skin cells and immune sensing cells, which both play vital yet distinct roles in HCMV infection. Understanding how HCMV and other viruses subvert necroptosis pathways will eventually allow us to develop vital new treatments to prevent diseases caused by HCMV. Crucially, this knowledge will also improve our understanding of cell death, which will benefit multiple lines of research including into sepsis, neurodegenerative disease and cancer. |
| Category | Research Grant |
| Reference | MR/X000516/1 |
| Status | Active |
| Funded period start | 01/04/2023 |
| Funded period end | 31/03/2026 |
| Funded value | £457,026.00 |
| Source | https://gtr.ukri.org/projects?ref=MR%2FX000516%2F1 |
Participating Organisations
| University of Cambridge |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: University of Cambridge, Cambridge.
The visualizations for "University of Cambridge - UK funding (£457,026): Novel mechanisms of necroptosis subversion by human cytomegalovirus"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
